期刊文献+

辐射对宫颈癌细胞EGFR核转运的影响 被引量:1

Effect of irradiation on EGFR nuclear translocation in cervical carcinoma cell lines
原文传递
导出
摘要 目的观察辐射对宫颈癌细胞表皮生长因子受体(EGFR)核转运的影响,并初步探讨EGFR核转运在宫颈癌细胞辐射抵抗当中的作用。方法通过免疫印记检测法分析了EGFR在宫颈腺癌细胞HeLa和Siha以及宫颈鳞癌细胞Caski中的表达,以及X线照射4Gy后Caski细胞核内EGFR和细胞浆内EGFR不同时间点的表达。并且分析了Cetuximab(C225)对辐射诱导的Caski细胞EGFR核表达影响及其生存分数的影响。结果3株宫颈癌细胞中Caski细胞系EGFR呈高表达。受照的Caski细胞核内EGFR受体表达随时间增多,胞质内EGFR受体减少。C225预处理后,辐射诱导的EGFR核表达明显降低并且生存分数降低。结论辐射能够诱导宫颈癌细胞EGFR核转运,并且EGFR核表达可能和放疗抵抗相关,核内EGFR在宫颈癌细胞放疗抵抗中的作用尚需进一步研究。 Objective To observe the EGFR nuclear translocation in cervical carcinoma cell lines after irradiation and its possible role in radiation tolerance. Methods Western blotting was used to detect the nuclear EGFR and cytoplastic EGFR after irradiation. The effect of Cetuximab on expression of nuclear EGFR and survival fractions were investigated. Results After irradiation, compared with control group, the expression of nuclear EGFR protein increased in irradiated cervical carcinoma cell. Cetuximab inhibited the radiation-induced nuclear EGFR expression with decreased survival fractions. Conclusion Radiation could induce EGFR nuclear translocation in cervical carcinoma cell lines and nuclear EGFR might be correlated with radiation tolerance in Cervical carcinoma cell.
出处 《中华放射医学与防护杂志》 CAS CSCD 北大核心 2009年第2期133-135,共3页 Chinese Journal of Radiological Medicine and Protection
基金 国家自然科学基金(30672426)
关键词 人类表皮生长因子受体 宫颈癌 辐射敏感性 EGFR Cervical carcinoma Radiosensitivity
  • 相关文献

参考文献8

  • 1Lo HW, Hsu SC, Hung MC. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res Treat, 2006,95 (3) : 211-218. 被引量:1
  • 2Dittmann K, Mayer C, Fehrenbacher B, et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem, 2005, 280 (35) : 31182-31189. 被引量:1
  • 3Pillai MR, Jayaprakash PG, Nair MK. Tumour-proliferative fraction and growth factor expression as markers of tumour response to radiotherapy in cancer of the uterine cervix. J Cancer Res Clin Oncol, 1998,124(8) :456-461. 被引量:1
  • 4Bellone S, Frera G, Landolfi G, et al. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease. Gynecol Oncol, 2007,106(3) :513-520. 被引量:1
  • 5刘俊丽,陈元,蔡煜,张敏.选择性EGFR酪氨酸激酶抑制剂吉非替尼对宫颈癌离体细胞的放射增敏作用[J].肿瘤防治研究,2007,34(7):480-482. 被引量:8
  • 6Contessa JN, Abell A, Valerie K, et al. ErbB receptor tyrosine kinase network inhibition radiosensitizes carcinoma ceils. Int J Radiat Oncol Biol Phys, 2006, 65(3):851-858. 被引量:1
  • 7Lin SY, Makino K, Xia W, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol, 2001,3(9) :802-808. 被引量:1
  • 8Lo HW, Hsu SC, Xia W, et al. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up- regulation of TWIST gene expression. Cancer Res, 2007,67 (19) :9066-9076. 被引量:1

二级参考文献7

  • 1刘俊丽,陈元,蔡煜.表皮生长因子受体酪氨酸激酶抑制剂ZD1839对宫颈癌细胞的作用[J].肿瘤防治研究,2006,33(7):512-515. 被引量:1
  • 2Ethier SP,Lawrence TS.Epidermal growth factor receptor signaling and response of cancer cells to ionizing radiation[J].Natl Cancer Inst,2001,93 (12):890-891. 被引量:1
  • 3Raymond E,Faivre S,Armand JP,et al.Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy[J].Drugs,2000,60(Suppl1):15-23. 被引量:1
  • 4Velu TJ.Structure,function and transforming potential of the epidermal growth factor receptor[J].Mol Cell Endocrinol,1990,70(3):205-216. 被引量:1
  • 5Giocanti N,Hennequin C,Rouillard D,et al.Additive interaction of gefitinib ('Iressa',ZD1839) and ionising radiation in human tumour cells in vitro[J].Br J Cancer,2004,91 (12):2026-2033. 被引量:1
  • 6Solomon B,Hagekyriakou J,Trivett M,et al.EGFR blockage with ZD1839 ("Iressa") potentiates the antitumor effects of single dose and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma[J].Int J Radiat Oncol Biol Phys,2003,55(3):713-723. 被引量:1
  • 7Chinnaiyan P,Huang S,Vallabhaneni G,et al.Mechanisms of Enhanced Radiation Response following Epidermal Growth Factor Receptor Signaling Inhibition by Erlotinib (Tarceva)[J].Cancer Res,2005,65 (8):3328-3335. 被引量:1

共引文献7

同被引文献21

  • 1曾益新.主编.肿瘤学.3版[M].北京:人民卫生出版社,2012:623-636. 被引量:1
  • 2胡联民,蔡凯.鼻咽癌治疗的研究进展[J].医学信息,2012.25(6):379-380. 被引量:1
  • 3张为远,吴玉梅,主编.官颈病变与官颈癌[M].北京:人民卫生出版社,2012:255-256. 被引量:1
  • 4Hackel PO, Zwick E, Prenzel N, et al. Epidermal growth factor reeeptors:eritieal mediators of multiple receptor pathways[J]. Curr Opin Cell Biol, 1999,11 (2) : 184-189. 被引量:1
  • 5Dewdney A, Cunningham D, Tabernero J, et al. Multicenter randomized phase Ⅱ clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C)[J]. J Clin Oncol, 2012, 30(14) : 1620-1627. 被引量:1
  • 6Sun PL, Li B, Ye QF. Effect of neoaajuvant cetuximab, capecitabine,and radiotherapy for locally advanced rectal cancer: results of a phase Ⅱ study[J].IntJ Coloreetal Dis, 2012,27(10): 1325-1332. 被引量:1
  • 7Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for loco regionally advanced head and neck cancer: 5- year survival data from a phase 3 randomized trial, and relation between cetuximab-induced rash and survival [ J]. I.aneet Oncol, 2010,11(1) :21-28. 被引量:1
  • 8Okano S,Yoshino T,Fujii M, et al. Phase Ⅱ study of cetuximab plus concomitant boost radiotherapy in Japanese patients with locally advanced squamous cell carcinoma of the head and neck[J]. Jpn J Clin Oncol,2013,43(5) :476-482. 被引量:1
  • 9Chen Y, Wu X, Bu S, et al. Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamouscell carcinoma[J]. Cancer Sci, 2012, 103 (11): 1979- 1984. 被引量:1
  • 10Crosby T, Hurt CN, Falk S, et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1) : a multicentre,phase 2/3 randomized trial[J]. Lancet Oncol, 2013, 14(7) : 627-637. 被引量:1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部